← All trials
NCT04526119
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 22, 2021
- Primary completion
- Feb 28, 2025
- Completion date
- Apr 30, 2025
- First posted
- Aug 25, 2020
- Last posted
- Mar 25, 2021
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zeria PharmaceuticalLead sponsor
- Zeria PharmaceuticalStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.